Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026
Same author

Long-Term Results of a Phase 2 Clinical Trial of Radiation Volume and Dose Deintensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

International journal of radiation oncology, biology, physics·2026
Same author

A retrospective cohort analysis evaluating the utility of the spinal instability neoplastic score (SINS) in screening for spinal instability and vertebral compression fracture risk in plasma cell neoplasm and lymphoma lesions.

The spine journal : official journal of the North American Spine Society·2026
Same author

Safety of Concurrent Systemic Therapy and Total Skin Electron Therapy in Cutaneous T-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

The oncologist·2026
Same author

Evaluating the dosimetric impact of intrafraction shifts on critical OAR doses for spine SBRT using an In-House simulator.

Technical innovations & patient support in radiation oncology·2026

Related Experiment Video

Updated: Apr 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Radiotherapy in Men with De Novo Metastatic Prostate Cancer.

Ian Messing1, Yuan James Rao2, Sharad Goyal3

  • 1Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.

The Urologic Clinics of North America
|April 15, 2026
PubMed
Summary

Adding radiotherapy to intensified systemic therapy improves survival for some metastatic prostate cancer patients. This approach offers benefits like delayed progression and manageable side effects for specific patient groups.

Keywords:
Low-volume metastatic diseaseRadiotherapyTreatment intensificationde novo metastatic prostate cancer

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Systemic therapy intensification has enhanced outcomes for de novo metastatic prostate cancer.
  • Retrospective studies suggested benefits of local radiotherapy for the primary tumor.
  • Prospective trials were initiated to evaluate the role of local radiotherapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of local radiotherapy in combination with intensified systemic therapy for metastatic prostate cancer.
  • To determine if local radiotherapy improves survival outcomes in patients with de novo metastatic prostate cancer.
  • To identify subgroups of patients who benefit most from the addition of local radiotherapy.

Main Methods:

  • Prospective evaluation through clinical trials such as HORRAD, STAMPEDE, and PEACE-1.
  • Comparison of intensified systemic therapy with and without local radiotherapy.
  • Assessment of overall survival, radiographic progression-free survival, and castrate resistance-free survival.

Main Results:

  • The HORRAD trial showed a trend toward improved survival with local radiotherapy.
  • The STAMPEDE trial demonstrated a statistically significant overall survival benefit in patients with lower-risk or lower-volume disease.
  • The PEACE-1 trial indicated benefits in radiographic progression-free survival and castrate resistance-free survival.

Conclusions:

  • Local radiotherapy is a valuable addition to intensified systemic therapy for selected patients with de novo metastatic prostate cancer.
  • The addition of radiotherapy can improve survival and delay disease progression in specific patient subgroups.
  • Further research may refine patient selection for combined modality treatment.